On September 24, 2021, Pharma-Bio Serv, Inc. (the "Company") resumed the
Company's stock repurchase program (the "Repurchase Program"). As of September
24, 2021, there were 1,658,846 shares of the Company's common stock available
for repurchase under the Repurchase Program. The timing, manner, price and
amount of any repurchases under the Repurchase Program will be at the discretion
of the Company, subject to the requirements of the Securities Exchange Act of
1934, as amended, and related rules. The Repurchase Program does not oblige the
Company to repurchase any shares and it may be modified, suspended or terminated
at any time and for any reason. No shares will be repurchased under the
Repurchase Program directly from directors or officers of the Company.
Pharma-Bio Serv, Inc. is a compliance and technology transfer services consulting company. The Company operates through four segments: Puerto Rico technical compliance consulting, United States technical compliance consulting, Europe technical compliance consulting, and Puerto Rico microbiological and chemical laboratory testing division (Lab). The Company provides a range of compliance-related consulting services. The Company provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. The Company's technical consulting services include regulatory compliance, validation, technology transfer, engineering, project management and process support. The Company markets its services to pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies in Puerto Rico, the United States, Europe and Brazil.
PHARMA-BIO SERV, INC. 